Global Dopamine Cell Replacement Therapy Clinical Trials, Companies & Market Trends Insight 2023 Report Highlights:
- Research Methodology
- Global Market Trends, Collaborations, Licensing & Financing
- Global Dopamine Cell Replacement Therapy Clinical Trials By Company, Indication & Phase
- Dopamine Cell Replacement Therapeutic Approach/Technology Platform By Company
- Dopamine Cell Replacement Therapy Future Outlook
- Insight On Key Companies Involved In Development Of Dopamine Cell Replacement Therapy
Download Report: https://www.kuickresearch.com/report-dopamine-cell-replacement-therapy
Dopamine cell replacement therapy is innovative and new therapeutic approach that has been suggested for the management and treatment of diseases caused by the deficiency of dopamine in the brain. Parkinson’s disease, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and many more. Though the major focus of companies developing these therapies is Parkinson’s disease and Alzheimer’s disease currently, the use of dopamine cell replacement therapy can be anticipated to expand and cover these indications in the coming years.
Dopamine is an essential chemical of the brain and is involved in several important functions of the human body such as motor skills, cognitive abilities, and reproduction. Therefore, it is reasonable that lowering of the levels of dopamine can have severe adverse effects one might want to evade. The current treatment approaches for these diseases are the administration of drugs to increase the levels of dopamine in the brain or signalling from the dopamine. However, these methods may not be effective in the long term or may give rise to adverse effects, which makes it important to develop alternative therapies that can provide long-term benefits.
Dopamine cell replacement therapy has emerged as a promising therapy in this aspect and a number of companies have now dived in to come up with the best dopamine-based cell therapies and to have their products approved. At present, dopamine-based cell therapies have been granted approval, and candidates are mostly in experimental and development phases. Some companies that are currently active in the market for dopamine cell replacement therapies are Brainstorm Cell Therapeutics, BlueRock Therapeutics and Aspen Neuroscience.
The idea of using dopamine for treating these diseases is not new; there are medications available that act as dopamine receptor agonists. However, the combination of this concept with cell therapy, particularly with stem cells, is an emerging and extremely promising therapeutic approach that has come up after years of research in both fields. The integration of these was a momentous step taken by researchers at a Swedish university in 1987 that has since fuelled the development of more dopamine cell replacement therapy.
The fundamental component of a dopamine cell replacement therapy is the transplantation of stem cells that, after developing into brain cells that can make dopamine, can do so. Some companies have chosen to collaborate with organizations that have better facilities in order to create stem cells that carry the weight of such crucial functions. For instance, Ryne Bio and Fujifilm Cellular Dynamics Inc. have partnered to provide exclusive licensing and manufacturing for their lead programme RNDP-001, which is an iPSC dopamine neuron progenitor being developed as a potential Parkinson’s disease disease-modifying therapy. Being a CDMO (contract development and manufacturing organization), Fujifilm has product manufacturing facilities that give it an edge over other companies, also making it an ideal partner for the development of stem cells for cellular therapies.
The market for dopamine cell replacement therapy is still in initial stages and is yet to be established in the global pharmaceutical market. Companies such as the ones mentioned above have taken the lead and results from their clinical trials have demonstrated the potential of dopamine cell replacement therapy for the management of Parkinson’s disease. Though these therapies are anticipated to be priced high because of the processes used in the development of these, adding these to the government’s reimbursement plans can help in bringing their costs down and increasing the availability among patients.